{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:33:40Z","timestamp":1785224020226,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Methotrexate (MTX) is a key drug in rheumatoid arthritis (RA) management but can rarely cause life-threatening hematologic toxicity, including therapy-related myelodysplastic syndrome (t-MDS), even at low doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 58-year-old male with RA on low-dose MTX (7.5\u00a0mg\/week) presented with pancytopenia. Evaluation showed Hb 5.7\u00a0g\/dL, TLC 1300\/\u03bcL, and platelets 63\u2009000\/\u03bcL. Nutritional deficiencies, infections, and autoimmune flare were excluded. Bone marrow examination revealed dysplasia with 11% blasts and abnormal precursors, suggestive of t-MDS. MTX and leflunomide were discontinued. He received leucovorin, G-CSF (Granulocyte colony stimulating factor), and supportive care. Rapid hematologic recovery was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the potential for low-dose MTX to cause t-MDS, which may be reversible if detected early. As serum MTX levels do not correlate with toxicity, regular blood count monitoring is essential. Prompt drug withdrawal and supportive therapy can lead to full recovery and prevent permanent marrow damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/omcr\/omaf253","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:47:28Z","timestamp":1761133648000},"source":"Crossref","is-referenced-by-count":2,"title":["Therapy related myelodysplastic syndrome: a hematologic sequela of low dose methotrexate in rheumatoid arthritis"],"prefix":"10.1093","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0804-0974","authenticated-orcid":false,"given":"Ayushi","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of General Medicine, Kasturba Medical College Mangalore, Manipal Academy of higher education, Manipal , 203, Light House Hill Road, Hampankatta, Mangaluru, Karnataka 575001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venugopala","family":"D","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kasturba Medical College Mangalore, Manipal Academy of higher education, Manipal , 203, Light House Hill Road, Hampankatta, Mangaluru, Karnataka 575001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alam","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kasturba Medical College Mangalore, Manipal Academy of higher education, Manipal , 203, Light House Hill Road, Hampankatta, Mangaluru, Karnataka 575001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3821-8117","authenticated-orcid":false,"given":"Vivek","family":"Hari","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Kasturba Medical College Mangalore, Manipal Academy of higher education, Manipal , 203, Light House Hill Road, Hampankatta, Mangaluru, Karnataka 575001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025121123112989300_ref1","doi-asserted-by":"publisher","first-page":"e40580","DOI":"10.7759\/cureus.40580","article-title":"Hypoplastic myelodysplastic syndrome: symptom of methotrexate toxicity in rheumatoid arthritis","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus."},{"key":"2025121123112989300_ref2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40744-020-00200-z","article-title":"Methotrexate discontinuation and dose decreases after therapy with tocilizumab: results from the Corrona rheumatoid arthritis registry","volume":"7","author":"Pappas","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025121123112989300_ref3","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2009.008326","article-title":"Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival","volume":"94","author":"Ongaro","year":"2009","journal-title":"Haematologica."},{"key":"2025121123112989300_ref4","doi-asserted-by":"publisher","first-page":"e2022030","DOI":"10.4084\/MJHID.2022.030","article-title":"De novo and therapy-related myelodysplastic syndromes: analogies and differences","volume":"14","author":"Leone","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2025121123112989300_ref5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41408-021-00547-8","article-title":"Therapeutic targeting of the inflammasome in myeloid malignancies","volume":"11","author":"Chakraborty","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025121123112989300_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4242-8","article-title":"How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?","volume":"37","author":"Cansu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025121123112989300_ref7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025121123112989300_ref8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1345\/aph.1C293","article-title":"Pancytopenia associated with leflunomide and methotrexate","volume":"37","author":"Hill","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2025121123112989300_ref9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/rheumatology\/kep406","article-title":"Severe aplastic anaemia following leflunomide therapy","volume":"49","author":"W\u00fcsthof","year":"2010","journal-title":"Rheumatology"},{"key":"2025121123112989300_ref10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00277-006-0249-3","article-title":"Secondary myelodysplastic syndrome after hydroxychloroquine therapy","volume":"86","author":"Muslimani","year":"2007","journal-title":"Ann Hematol"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/11\/omaf253\/65549680\/omaf253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/11\/omaf253\/65549680\/omaf253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:11:33Z","timestamp":1765512693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaf253\/8343280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaf253","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"omaf253"}}